

VPA10996/289/001

Nobivac Pi lyophilisate and solvent for suspension for injection for dogs

Variation	Summary	Date
Vet - F.II.a.3 b) 2.	VRA-S - Vet - F.II.a.3 b) 2. - b) Other excipients 2. Change that relates to a biological/immunological product - F.II.a.3 b) 2. Quality Changes - Finished Product - Description and composition - Changes in the composition (excipients) of the finished product - Other excipients - Change that relates to a biological/immunological product	12/02/24
Vet - F.II.d.2 z)	VRA-R - Vet - F.II.d.2 z) - z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.II.d.2 z) Quality Changes - Finished Product -Control of finished product - Change in test procedure for the finished product - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	30/05/23
Vet - F.II.b.3 c)	VRA-S - Vet - F.II.b.3 c) - c) The product is a biological/immunological veterinary medicinal medicinal product and the change requires an assessment of comparability - F.II.b.3 c) Quality Changes - Finished Product -Manufacture - Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - The product is a biological/immunological veterinary medicinal medicinal product and the change requires an assessment of comparability	30/05/23
Vet - F.I.b.2 z)	VRA-R - Vet - F.I.b.2 z) - z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.I.b.2 z) Quality Changes - Active Substance - Control of active substance - Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	30/05/23